metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus cabozantinib
	atezolizumab plus cabozantinib
	CONTACT-03, 2023 Lancet 2023; 402:185-195-. NCT04338269	RCT	metastatic/advanced RCC (mRCC) - 2nd line (L2)	atezolizumab plus cabozantinib	cabozantinib alone	Patients aged 18 years or older with locally advanced or metastatic renal cell carcinoma whose disease had progressed with immune checkpoint inhibitors	263 / 259	low	inconclusive	inconclusive 6 % decrease in deaths (OS) (PE) inconclusive 3 % increase in progression or deaths (PFS) (PE)
versus everolimus
	nivolumab alone
	CheckMate 025, 2015 N Engl J Med 2015;373:1803-13 Jpn. J. Clin. Oncol. 2019; 49:506-514 Jpn. J. Clin. Oncol. 2017; 47:639-646 Eur. Urol. 2017; 72:368-376 Eur. Urol. 2017; 72:962-971 Lancet Oncol. 2016; 17:994-1003 NCT01668784	RCT	metastatic/advanced RCC (mRCC) - 2nd line (L2)	nivolumab	everolimus	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	410 / 411	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 5.0-fold increase in objective responses (ORR) (PE)